Clinical Trial Update: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial comparing FOLFOX with or without aflibercept in KRAS-mutant metastatic colorectal cancer with liver metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Aflibercept (Aflibercept)
• FOLFOX

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Colorectal Cancer Metastatic, Liver Metastases | Phase 2, Phase 3 | Status: WITHDRAWN